IPO Journey

Veradermics, Inc

IPO Date: April 30, 2026 · 5 filings tracked

Final Offer Terms

Ticker

MANE

Exchange

New York Stock Exchange

Offer Price

$100

Shares Offered

3,843,790

Estimated Proceeds

$384.4M

Underwriters

Led by Jefferies, Leerink Partners

S-1

January 9, 2026

Targeting a massive market of 80 million Americans suffering from pattern hair loss.
Developing VDPHL01, a potential first-in-class oral, non-hormonal treatment for female pattern hair loss.

S-1/A

January 28, 2026

Developing VDPHL01, a potential first-in-class oral, non-hormonal treatment for female pattern hair loss.
Targeting a massive aesthetic dermatology market with a once-daily pill solution.

Changes from previous filing

424B4 Material Update

February 4, 2026

Developing VDPHL01, a potentially first-of-its-kind extended-release oral minoxidil for female hair loss.
Targeting a massive $9 billion annual hair loss market.

Changes from previous filing

S-1

April 27, 2026

Developing VDPHL01, a novel oral, non-hormonal pill for pattern hair loss
Positive Phase 2 study results with 519 participants showing increased hair counts

Changes from previous filing

▸ Shares offered: 3,350,000
▸ Underwriters: Jefferies, Leerink Partners, Citigroup, Cantor, LifeSci Capital, Needham & Company

424B4 Final Pricing

April 30, 2026

Developing VDPHL01, a potential first-to-market oral minoxidil for female hair loss
Successful Phase 3 clinical trial results with 519 participants showing significant hair growth

Changes from previous filing

Disclaimer: AI-generated analysis for informational purposes only. Not financial advice. Always conduct your own research.